Late-stage clinical trials incur the biggest costs of bringing new drugs to market. Increasingly clinical trial failures happen late. In around 60% of cases these failures are due to the complexity of disease biology and failure to demonstrate efficacy.
At the same time, health systems are spending 85% of their treatment budgets on patients without effective treatment options in a wide range of chronic diseases.
In this article, Dr Steve Gardner, CEO PrecisionLife, examines the lack of return on investment for pharmaceutical R&D and the huge pockets of unmet medical need in common chronic disorders. Read the paper, Complexity of Disease Biology, to find out how combinatorial analysis is helping to overcome this challenge.
Drug Discovery World | Volume 22 | Issue 3 | July 2021